Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stephens & Co. Reiterates Equal-Weight on Lifecore Biomedical, Maintains $6 Price Target

Author: Benzinga Newsdesk | January 03, 2025 10:08am
Stephens & Co. analyst Jacob Johnson reiterates Lifecore Biomedical (NASDAQ:LFCR) with a Equal-Weight and maintains $6 price target.

Posted In: LFCR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist